Company / Interest Expense
ANI Pharmaceuticals, Inc. Interest Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$32.6M
FY2025
5-year range
$11.9M / $35.6M
FY2021-FY2025
Trend
-3.2%
vs FY2024
Sector context
#16 of 44
Health Care
What the data says
At $33M, ANI Pharmaceuticals, Inc.'s interest expense ranks #29 of 44 in the Health Care sector. Interest Expense has fluctuated over the past 10 years, ranging from $9M in FY2020 to $36M in FY2023.
Based on SEC 10-K filings.
$33M in FY2025 with a 5-year CAGR of +28.0%.
Improved from $36M to $33M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +4.5%
- 5-Year CAGR
- +28.0%
- 10-Year CAGR
- -
Sector benchmark
#29 of 44 in Health CareTop 64% of 44This company $32.6M Sector average $291.0M
▼
-88.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +28.0%, indicating consistent growth.
- In FY2025, interest expense decreased 3.2% year-over-year.
- Ranks #16 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $32.6M | -3.2% |
| FY2024 | $33.6M | -5.6% |
| FY2023 | $35.6M | +25.0% |
| FY2022 | $28.5M | +138.7% |
| FY2021 | $11.9M | +26.0% |
| FY2020 | $9.5M | -29.6% |
| FY2019 | $13.5M | -9.7% |
| FY2018 | $14.9M | +31.7% |
| FY2017 | $11.3M | +0.3% |
| FY2016 | $11.3M | +1292.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026